Bausch & Lomb
This article was originally published in The Gray Sheet
Firm commences hostile takeover bid for tinted contact lens maker Wesley Jessen April 3 via $34-per-share tender offer (1"The Gray Sheet" April 3, In Brief). Separately, B&L filed a lawsuit in the Court of Chancery of Delaware against Wesley Jessen and Ocular Sciences seeking "injunctive relief" against the Wesley Jessen/Ocular Sciences merger agreement of March 20, redemption of Wesley Jessen's "poison pill" anti-takeover provisions and "a declaration that any breakup fee Ocular receives it holds as a constructive trustee," B&L states
You may also be interested in...
Lawsuit filed in California state court seeks injunctive relief, compensatory and punitive damages from Bausch & Lomb for tortious interference with the March 20 definitive merger agreement between Ocular and Wesley Jessen. The suit is the latest salvo in a tug of war for Wesley Jessen. B&L launched a hostile $34-per-share takeover bid for Wesley Jessen April 3 and filed a lawsuit against Wesley Jessen and Ocular seeking injunctive relief against the merger in the Court of Chancery of Delaware (1"The Gray Sheet" April 10, In Brief)
Medical products that do not fully comply with Canadian requirements but are manufactured according to comparable standards are being allowed into the country to deal with COVID-19-related shortages.